Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant nab-paclitaxel plus gemcitabine versus gemcitabine alone after resection of pancreatic adenocarcinoma
NL-OMON50589Phase 3Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) comparing nab-paclitaxel + gemcitabine with gemcitabine alone (2 arms). Primary endpoint: Disease-free survival. Started Feb 2016; status: active, not recruiting.
02
Drugs
paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON50589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50589.